Scarica l'app Stockscreener
485.51
3.31%
15.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$470.27
Aprire:
$474.39
Volume 24 ore:
432.58K
Relative Volume:
0.37
Capitalizzazione di mercato:
$63.61B
Reddito:
$2.46B
Utile/perdita netta:
$-319.09M
Rapporto P/E:
-196.81
EPS:
-2.4669
Flusso di cassa netto:
$-52.09M
1 W Prestazione:
+6.32%
1M Prestazione:
+5.33%
6M Prestazione:
+110.77%
1 anno Prestazione:
+61.64%
Intervallo 1D:
$470.46
$488.38
Intervallo di 1 settimana:
$451.00
$488.38
Portata 52W:
$205.87
$488.38
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
485.31 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.63 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.95 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
831.04 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.36 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Alnylam Pharmaceuticals stock hits all-time high at 484.5 USD By Investing.com - Investing.com Nigeria
Are You Looking for a Top Momentum Pick? Why Alnylam Pharmaceuticals (ALNY) is a Great Choice - Yahoo Finance
Custom watchlist performance reports with Alnylam Pharmaceuticals Inc.2025 Top Gainers & Fast Moving Stock Trade Plans - newser.com
Alnylam Pharmaceuticals stock hits all-time high at 484.5 USD - Investing.com India
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock? - Zacks Investment Research
What Catalysts Are Shaping the Evolving Narrative for Alnylam Pharmaceuticals? - Yahoo Finance
Is Alnylam Pharmaceuticals Inc. stock ready for breakoutAnalyst Upgrade & Free High Accuracy Swing Entry Alerts - newser.com
The Bull Case For Alnylam Pharmaceuticals (ALNY) Could Change Following Phase 3 ZENITH Study Launch for Zilebesiran - simplywall.st
Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock - Yahoo Finance
Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Will Alnylam Pharmaceuticals Inc. stock sustain high P E ratiosJuly 2025 Update & Safe Capital Allocation Plans - newser.com
Has Alnylam Pharmaceuticals Inc. found a price floorMarket Risk Summary & Verified Swing Trading Watchlist - newser.com
JP Morgan Lowers Price Target for ALNY, Maintains Overweight Rat - GuruFocus
What earnings revisions data tells us about Alnylam Pharmaceuticals Inc.Weekly Stock Report & Fast Moving Trade Plans - newser.com
Alnylam Pharma Secures $500M Credit Agreement - MSN
Vontobel Holding Ltd. Has $951,000 Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Callan Family Office LLC Raises Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Leader with a Robust Pipeline and Strong Buy Ratings - DirectorsTalk Interviews
What to do if you’re stuck in Alnylam Pharmaceuticals Inc.2025 Technical Overview & High Accuracy Trade Alerts - newser.com
Sivik Global Healthcare LLC Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Aberdeen Group plc Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY): Valuation Snapshot Following New Phase 3 Data and Pipeline Progress - simplywall.st
Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from HC Wainwright - MarketBeat
H.C. Wainwright Reaffirms Their Buy Rating on Alnylam Pharma (ALNY) - The Globe and Mail
Is Alnylam Pharmaceuticals Inc. (DUL) stock attractive for dividend growthJuly 2025 Catalysts & High Accuracy Swing Trade Signals - newser.com
ALNY: HC Wainwright & Co. Reiterates Buy Rating with $570 Price Target | ALNY Stock News - GuruFocus
Is Alnylam Pharmaceuticals Inc. stock ready for a breakoutJuly 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com
Using AI based signals to follow Alnylam Pharmaceuticals Inc.Trade Volume Summary & High Conviction Buy Zone Alerts - newser.com
What drives Alnylam Pharmaceuticals Inc stock priceGlobal Trade Effects & Access Risk Ratings for Every Stock - earlytimes.in
Alnylam and Regeneron Join Forces in Promising Alzheimer’s Study - TipRanks
KLP Kapitalforvaltning AS Has $16.01 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Shell Asset Management Co. Purchases 1,602 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Mirae Asset Global Investments Co. Ltd. Has $1.56 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Weiss Ratings Reaffirms "Sell (D-)" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Alnylam’s AMVUTTRA Reduces GI Events in ATTR-CM Patients, According to New HELIOS-B Data - MSN
Amyloidosis Clinical Market Outlook 2024-2034: Expanding Diagnostic Capabilities - openPR.com
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know - Benzinga
Did Amvuttra’s Phase 3 Update and ZENITH Trial Milestone Just Shift Alnylam’s (ALNY) Investment Narrative? - simplywall.st
Alnylam Pharmaceuticals (ALNY) Gets Target Price Boost from Morg - GuruFocus
Morgan Stanley Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $475.00 - MarketBeat
Stifel Raises Price Target for ALNY; Maintains 'Buy' Rating | AL - GuruFocus
Smart tools for monitoring Alnylam Pharmaceuticals Inc.’s price action2025 Bull vs Bear & Short-Term Trading Alerts - newser.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $495.00 Price Target at Stifel Nicolaus - MarketBeat
Morgan Stanley Raises Price Target on Alnylam Pharmaceuticals to $475 From $405, Keeps Equalweight Rating - MarketScreener
Is Alnylam Pharmaceuticals Inc. (DUL) stock a top hedge fund pickWeekly Investment Recap & Smart Money Movement Tracker - newser.com
News impact scoring models applied to Alnylam Pharmaceuticals Inc.Forecast Cut & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Alnylam Pharmaceuticals Inc a good long term investmentStraddle and Strangle Trades & Superior Wealth Growth - earlytimes.in
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Exploring Growth Potential and Investment Risks in Biotech - DirectorsTalk Interviews
Is Alnylam Pharmaceuticals Inc DUL a good long term investmentGlobal Trade Effects & Build Wealth Brick by Brick With Us - earlytimes.in
Will Alnylam Pharmaceuticals Inc. (DUL) stock announce special dividendWeekly Loss Report & Accurate Intraday Trading Signals - newser.com
What indicators show strength in Alnylam Pharmaceuticals Inc.Quarterly Profit Report & Advanced Swing Trade Entry Alerts - newser.com
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alnylam Pharmaceuticals Inc Azioni (ALNY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Oct 02 '25 |
Sale |
452.05 |
8,924 |
4,034,085 |
65,409 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Oct 02 '25 |
Sale |
452.05 |
1,405 |
635,126 |
27,438 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Oct 02 '25 |
Sale |
452.05 |
2,441 |
1,103,451 |
25,231 |
| Garg Pushkal | EVP Chief R&D |
Oct 03 '25 |
Sale |
451.48 |
3,022 |
1,364,387 |
20,221 |
| Garg Pushkal | EVP Chief R&D |
Oct 02 '25 |
Sale |
452.05 |
2,937 |
1,327,675 |
23,243 |
0.63%
2.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):